Dr. Reddy's Recalls Zenatane Capsules Due to Dissolution Failure
Dr. Reddy's Laboratories is recalling Zenatane (isotretinoin) capsules because they failed to meet dissolution specifications. The recall covers 4,404 cartons distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which by definition is unlikely to cause adverse health consequences, fitting the 'Low' severity criteria for documentation or minor specification issues.
Plain-English summary
Dr. Reddy's Laboratories, Inc. is recalling Zenatane (isotretinoin) capsules, 10 mg, packaged in 30-count cartons. The recall involves 4,404 cartons of the medication, which was distributed nationwide in the United States. The specific lot affected is KB60197, with an expiration date of 2/18.
The recall was initiated because the product failed to meet dissolution specifications, specifically showing low dissolution results at the S3 stage. Dissolution is a critical quality attribute that ensures the medication breaks down properly in the body to be absorbed effectively.
Consumers who have this specific lot of Zenatane should stop using it and contact their healthcare provider or pharmacist for guidance. The FDA has classified this recall as Class III, indicating that the violation of the product's labeling or manufacturing specifications is not likely to cause adverse health consequences.
The recalled product
- Product
- ZENATANE (ISOTRETINOIN)
- Brand
- ZENATANE
- Manufacturer
- Dr. Reddy's Laboratories, Inc.
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 4,404
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # KB60197
- Exp 2/18
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Dr. Reddy's Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same brand · ZENATANE
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failure
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Capsules for Low Dissolution
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failures
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Isotretinoin Capsules for Dissolution Failures
FDA (Drugs) · 2017-06-14
- ModerateDr. Reddy's Recalls Zenatane Capsules Due to Dissolution Failures
FDA (Drugs) · 2017-03-08
Same manufacturer · Dr. Reddy's Laboratories, Inc.
See all →- ModerateVarenicline tablets recalled after an assay value fell below specification
FDA (Drugs) · 2025-12-17
- Moderate
- HighOmeprazole capsule bottle contained a foreign divalproex sodium tablet
FDA (Drugs) · 2025-07-23
- SevereLevetiracetam Injection Label Mismatch Nationwide Recall
FDA (Drugs) · 2025-04-23
- ModerateFDA Recalls JAVYGTOR Tablets Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-12-18
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17